Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma

Mantle Cell Lymphoma Clinical Trial

Official title:

A Pilot Phase II Trial of Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00183989
• Other study ID #: 13NHL-99-2
• Status: Terminated
• Phase: Phase 2
• First received: September 12, 2005
• Last updated: May 20, 2014
• Start date: August 2000
• Est. completion date: December 2006

Study information

• Verified date: May 2014
• Source: University of Southern California
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study is being done in order to determine the effectiveness of the combination of fludarabine, mitoxantrone, and rituximab in patients with mantle cell lymphoma. All three drugs,fludarabine, mitoxantrone, and rituximab have been approved by the U.S. Food and Drug Administration (FDA)for the treatment of certain types of lymphoma. Rituximab is a drug (called a monoclonal antibody) which has anti-tumor activity on certain types of lymphoma. The combination of chemotherapy (fludarabine and mitoxantrone) with rituximab has not yet been investigated in patients with mantle cell lymphoma and therefore the combination in investigational.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 30
• Est. completion date: December 2006
• Est. primary completion date: December 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologic diagnosis of Non-Hodgkin's Lymphoma of the mantle cell sub-type lymphoma only, as determined by morphologic assessment and consistent immunophemotypic markers

• Newly diagnosed and patients who have received prior treatment are eligible

• Measurable or evaluable disease

• Karnofsky performance status greater or equal to 50%

• Men and women, age greater or equal to 18 years old

• AGC greater or equal to 1.0; platelets greater or equal to 75,000; Hemoglobin greater or equal to 8.0 (unless because of lymphomatous infiltration of the marrow)

• Creatinine less than 2.0; bilirubin less than 2.0; SGOT less than 3 times upper limit of normal (unless elevations are due to lymphomatous involvement)

• Women of child bearing potential must have negative pregnancy test within 14 days of study entry.

• Signed informed consent

Exclusion Criteria:

• History of congestive heart failure or significant cardiac disease

• Prior exposure to either fludarabine or mitoxantrone. Prior exposure to rituximab allowed

• Active infection

• HIV seropositive

• Pregnant or lactating females

• Second active malignancy, other than squamous cell skin cancer,in-situ cervical cancer, or history of other cancer diagnosed within the preceding 5 years

• Presence of psychological or emotional disorders which would make valid informed consent impossible

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Mantle-Cell
• Mantle Cell Lymphoma

Intervention

Drug:
• Fludarabine, Mitoxantrone and Rituximab

Locations

Country	Name	City	State
United States	Norris Comprehensive Cancer Center	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
University of Southern California

Country where clinical trial is conducted

United States,